4-(Aminomethyl)tetrahydro-2H-pyran-4-carbonitrile - CAS 1263374-32-8
Catalog: |
BB054959 |
Product Name: |
4-(Aminomethyl)tetrahydro-2H-pyran-4-carbonitrile |
CAS: |
1263374-32-8 |
Synonyms: |
4-(aminomethyl)tetrahydro-2H-pyran-4-carbonitrile; 4-(aminomethyl)oxane-4-carbonitrile; 2H-Pyran-4-carbonitrile, 4-(aminomethyl)tetrahydro-; 4-(Aminomethy)oxane-4-carbonitrile |
IUPAC Name: | 4-(aminomethyl)oxane-4-carbonitrile |
Molecular Weight: | 140.18 |
Molecular Formula: | C7H12N2O |
Canonical SMILES: | C1COCCC1(CN)C#N |
InChI: | InChI=1S/C7H12N2O/c8-5-7(6-9)1-3-10-4-2-7/h1-5,8H2 |
InChI Key: | WRAFVYHNHMNOCQ-UHFFFAOYSA-N |
GHS Hazard Statement: | H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P260, P261, P264, P270, P271, P280, P301+P317, P301+P330+P331, P302+P352, P302+P361+P354, P304+P340, P305+P354+P338, P316, P317, P319, P321, P330, P362+P364, P363, P403+P233, P405, and P501 |
Signal Word: | Danger |
Publication Number | Title | Priority Date |
AU-2015299149-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | 20140804 |
CA-2957046-A1 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | 20140804 |
EP-3177612-A1 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | 20140804 |
JP-2017523193-A | Compounds active against nuclear receptors | 20140804 |
JP-2020023534-A | Compounds active on nuclear receptors | 20140804 |
JP-6604664-B2 | Compounds active against nuclear receptors | 20140804 |
RU-2719422-C2 | Optionally condensed heterocyclyl-substituted pyrimidine derivatives suitable for treating inflammatory, metabolic, oncological and autoimmune diseases | 20140804 |
US-10683293-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | 20140804 |
US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | 20140804 |
US-2017327503-A1 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | 20140804 |
Complexity: | 152 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 140.094963011 |
Formal Charge: | 0 |
Heavy Atom Count: | 10 |
Hydrogen Bond Acceptor Count: | 3 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 140.094963011 |
Rotatable Bond Count: | 1 |
Topological Polar Surface Area: | 59Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | -0.8 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS